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Many researchers consider that the HIV viral load assay 
is a useful marker for disease progression in HIV- 
infected patients treated with antiviral drugs. O n  the 
other hand, the conclusions of a recent Food and Drug 
Administration (FDA)-sponsored meeting [1] were 
that, in the design of clinical trials of anti-HIV drugs, 
there is a lack ofvalid clinical and immunologic criteria. 
To clarify the interrelation between viral replication and 
disease progression, we have carried out an initial study 
of the HIV KNA load (determined by the Amplicor 
Koche System) and its correlation with CD4 cells at  
different times of HIV disease in the same patients with 
HIV disease. 
Seven HIV-positive patients, sex and age matched, 
with a CD4 cell counts < 100 110 mm3, who had been 
treated with zidovudine (250 mg twice daily) plus 
zalcitabine (0.75 mg three times daily) for at  least 6 
months, were evaluated prospectively. At the time of 
enrolment (after 6 or more months of therapy), a 
definite diagnosis of neurotoxoplasmosis had been 
made. HIV R N A  load and CD4 cell count were 
determined before and 3 weeks after specific therapy 
(sulfadiazine, 1 g four times daily, and pyriniethamine 
25 mg twice daily) was started. As reported in Table 1, 
our data showed a significant difference (p<O.001 by 
means of linear regression) in HIV load between the 
patients at the time of the neurotoxoplasmosis and after 
3 weeks’ treatment, and no correlation between CD4 
cell count and HIV load at the two times of estimation. 
There was no significant difference in CD4 cell counts 
( ~ 0 . 9 3 0 ;  p’0.002) on the two occasions. 
Various inferences can be drawn from these results. 
Neurotoxoplasmosis may induce immune activation of 
latently infected cells, as reported by others [Z], and 
Table 1 HIV R N A  load and CD4 cell count at the time 
of neurotoxoplasmosis (baseline) and after 3 weeks of 
antitoxoplasnia treatment 
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this may being about a transient increase in viral load. 
The plasma viral load appears to be unrelated to the rate 
of CD4+ T-cell destruction. In spite of continuous 
antiviral treatment, the viral load may increase during 
opportunistic infections. These data cast doubt on the 
use of the measurement of HIV load in the plasma to 
evaluate HIV progression, particularly in patients in the 
advanced stages of HIV infection. We think it possible 
that plasma viral load is a direct reflection of viral 
replication modified by different factors as mentioned 
above. It seems that the measurement of CD4 cell 
count remains the single best means of documenting 
HIV progression. 
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Cytomegalovirus (CMV) commonly infects humans 
throughout the world. After the primary infection, the 
virus remains in a latent state in the host. In clinically 
healthy individuals, reactivation of latent virus frequently 
results in asymptoniatic excretion of CMV; the virus 
may be excreted in genital secretions and sexually 
transmitted 111. CMV may cause severe congenital 
disease when a primary infection occurs during the 
course of pregnancy. A less severe congenital infection 
may also result from a secondary maternal infection [2] 
due to reactivation of the latent virus or infection with 
a new viral strain [3]. O n  the other hand, direct 
contamination of the fetus is theoretically possible 
through germ cells and spermatozoa [4]. Therefore, 
semen samples collected from CMV-seropositive sperm 
donors constitute a possible source of CMV infection 
for women involved in a therapeutic donor insernina- 
tion (TDI) and may bring about a congenital CMV 
